Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Impact of the 2011 NICE guidance on dementia drugs in a neurology-led memory clinic

AJ Larner
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.12-5-496
Clin Med October 2012
AJ Larner
Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Liverpool, UK
Roles: Consultant neurologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

The most recent guidance published by the National Institute for Health and Clinical Excellence (NICE) on the use of the anti-dementia drugs cholinesterase inhibitors (ChEI) and memantine in Alzheimer's disease (AD) and other dementias (NICE217)1 made these drugs available as per licence, effective from 1 June 2011. The guidance made these drugs more easily accessible than had previously been the case following previous NICE guidance published in 2006 (NICE111). It was anticipated that one effect of this liberalisation of drug availability would be that more people who might be candidates for licensed use of these medications (ie mild to moderate AD and Parkinson's disease dementia) would be referred to dementia/memory clinics, with a possible diminution in the recognised dementia ‘diagnosis gap’ resulting from too few people being diagnosed with dementia and too few of those diagnosed being diagnosed early enough.2

The possible impact of NICE217 in a neurology-led memory service was examined by comparing referral numbers, sources, patient diagnoses and candidacy for treatment with cholinesterase inhibitors in the 12-month periods immediately before (1 June 2010–31 May 2011) and after (1 June 2011–31 May 2012) publication of the NICE217 guidance (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Referral numbers, sources, patient diagnoses and candidacy for ChEI/memantine treatment before and after NICE217 effective.

These data showed no change in the number of new referrals between the two time periods, but did show an increase in the percentage of referrals coming from primary care in the second time period (82.7% vs 73.5%). The null hypothesis that the proportion of new referrals from primary care was the same in the cohorts referred before and after NICE217 (equivalence hypothesis) was rejected (χ2 = 5.12, df = 1, p<0.05). However, there was no change in the percentage of patients receiving a diagnosis of dementia (DSM-IV-TR criteria; χ2 = 0.17, df = 1, p0.5).

The proportion of patients deemed candidates for treatment with ChEI or memantine was examined. Exclusions included patients with frontotemporal lobar degenerations, vascular dementia or subcortical ischaemic vascular dementia, dementia with Lewy bodies, Huntington's disease, Down syndrome, alcohol-related dementia, and prion disease, since these conditions fall out with the drug licence, although ChEIs have sometimes been used.3 This analysis showed no change in the proportion of patients suitable for these medications, examining either the whole cohort (χ2 = 0) or those patients with dementia only (χ2 = 0.56, df = 1, p0.5).

Previous UK national dementia directives, NICE and the Social Care Institute for Excellence (SCIE) guidelines of November 2006, and the National Dementia Strategy (NDS) of February 2009, were associated with increased referrals to a neurology-led memory clinic; although much of the increase was due to individuals without evidence of dementia – and hence not candidates for drug treatment – being referred from primary care.4,5 In the year since NICE217 became effective, no similar increase in referrals to the clinic has been observed, but there has been a continuing increase in referrals from primary care. To date, the increased availability of dementia drugs consequent upon NICE217 has not been associated with any evidence for closure of the dementia diagnosis gap. Although it is too early for definitive conclusions, this study does further highlight the gap between policy intent and what happens in practice.

Footnotes

  • Letters not directly related to articles published in Clinical Medicine and presenting unpublished original data should be submitted for publication in this section. Clinical and scientific letters should not exceed 500 words and may include one table and up to five references.

  • © 2012 Royal College of Physicians

References

  1. ↵
    National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 111. NICE technology appraisal guidance 217. London: NICE, 2011
  2. ↵
    Alzheimer's Society. Mapping the Dementia Gap: Study produced by Tesco, Alzheimer's Society and Alzheimer's Scotland. London: Alzheimer's Society, 2011
  3. ↵
    1. Larner AJ
    . Cholinesterase inhibitors – beyond Alzheimer's disease. Expert Rev Neurother 2010;10:1699–705
    OpenUrlCrossRefPubMed
  4. ↵
    1. Larner AJ
    . Impact of the National Institute for Health and Clinical Excellence and Social Care Institute for Excellence's dementia guidelines in a neurology-led memory clinic. Clin Med 2009;9:197–8
    OpenUrlPubMed
  5. ↵
    1. Larner AJ
    . Impact of the National Dementia Strategy in a neurology-led memory clinic. Clin Med 2010;10:526
    OpenUrlFREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Impact of the 2011 NICE guidance on dementia drugs in a neurology-led memory clinic
AJ Larner
Clinical Medicine Oct 2012, 12 (5) 496; DOI: 10.7861/clinmedicine.12-5-496

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of the 2011 NICE guidance on dementia drugs in a neurology-led memory clinic
AJ Larner
Clinical Medicine Oct 2012, 12 (5) 496; DOI: 10.7861/clinmedicine.12-5-496
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Impact of the National Dementia Strategy in a neurology-led memory clinic: 5-year data
  • Google Scholar

More in this TOC Section

Letters to the Editor

  • JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides
  • Response
  • Functional disorders and chronic pain
Show more Letters to the Editor

Clinical and Scientific Letters

  • Does ultrasound-guided peripheral cannulation training for junior doctors reduce missed intravenous antibiotics doses? A teaching programme for foundation doctors in an acute medical unit
  • Unexpected deaths following discharge of medical patients from hospital
  • Promoting electric vehicle uptake, a job for the NHS?
Show more Clinical and Scientific Letters

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians